The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

AI-generated analysis

πŸ“ˆ Total revenue increased 1% year-over-year to $1.066 billion in Q3 fiscal 2026, with adjusted diluted EPS jumping 4% to $1.15.

πŸ’° The company repurchased approximately 4.9 million shares for $339.1 million, leaving $1.5 billion in remaining buyback capacity after raising authorization to $3 billion.

πŸš€ Free cash flow surged 66% to a record $273.0 million, driven by $341.7 million in operating cash flow and reduced capital spending of $68.7 million.

πŸ“‰ GAAP gross margins expanded to 67%, while adjusted operating margins improved 30 basis points to 26% supported by cost discipline despite currency headwinds.

πŸ₯ The fertility segment within CooperSurgical delivered notable growth, successfully offsetting weakness in the CooperVision ophthalmic division.

πŸ“‰ CooperVision revenue fell below consensus estimates due to U.S. channel inventory reductions and a 10% drop in Asia Pacific sales.

πŸ“‰ Management lowered full-year fiscal 2026 revenue guidance to $4.229 billion–$4.252 billion, implying organic growth of 2% to 3%.

🎯 The company reiterated its long-term free cash flow target of exceeding $2.2 billion through FY28, aligning with strategic priorities for shareholder value.

🏦 BlackRock remains the largest institutional investor with a 7.71% stake, while hedge fund interest increased to 52 funds holding positions in Q2 2026.

Bullish Signals
  • Adjusted diluted EPS jumped 4% year-over-year to $1.15, exceeding market projections and demonstrating strong profitability.
  • Free cash flow surged 66% to a record $273.0 million, providing substantial flexibility for capital returns and strategic investments.
  • The fertility segment within CooperSurgical delivered notable growth, acting as a key driver of overall revenue expansion.
  • GAAP gross margins expanded to 67%, reflecting improved pricing power and the absence of prior inventory write-downs.
  • Adjusted operating margins improved by 30 basis points to 26%, supported by effective cost discipline and productivity gains.
Risk Factors
  • Management lowered full-year fiscal 2026 revenue guidance to a range of $4.229 billion to $4.252 billion, implying modest organic growth of 2% to 3%.
  • CooperVision segment revenue fell below consensus estimates due to U.S. channel inventory reductions and a 10% drop in Asia Pacific sales.
  • Currency headwinds negatively impacted adjusted gross margins, causing a 60 basis point drop from the prior year's adjusted figure.
Full Analysis
The Cooper Companies (COO) reported third-quarter fiscal 2026 results with total revenue rising 1% year-over-year to $1.066 billion, driven by a 4% increase in adjusted diluted EPS to $1.15. The company executed significant capital return programs, repurchasing approximately 4.9 million shares for $339.1 million while maintaining $1.5 billion in remaining buyback capacity following a board authorization increase from $2 billion to $3 billion. Financial performance was bolstered by record free cash flow generation of $273.0 million, a 66% surge driven by strong operating cash flow and disciplined capital spending. GAAP gross margins expanded to 67%, aided by the absence of prior inventory write-downs, while adjusted operating margins improved 30 basis points to 26% despite currency headwinds. The fertility segment within CooperSurgical delivered notable growth, offsetting weakness in the CooperVision ophthalmic division. Despite strong quarterly execution and a robust balance sheet, management lowered its full-year fiscal 2026 revenue guidance to a range of $4.229 billion to $4.252 billion, implying organic growth of 2% to 3%. The company reiterated its long-term free cash flow target of exceeding $2.2 billion through FY28, signaling continued commitment to profitable expansion and efficient capital deployment even as it navigates regional headwinds in the lens business. Institutional ownership remains stable with BlackRock holding 7.71% of outstanding shares, while hedge fund interest saw a marginal increase with positions held by 52 funds at the end of Q2 2026. The stock trades with a short interest of 4%, reflecting modest active betting against the name as investors weigh the company's strategic priorities against near-term macroeconomic and currency pressures.